Loading...
Loading...
Loading...
- Albireo Pharma Inc ALBO has agreed to sell its Priority Review Voucher (PRV) for $105 million.
- The FDA granted the PRV for Bylvay to treat pruritus in all types of progressive familial intrahepatic cholestasis (PFIC).
- Related Content: Albireo's Rare Liver Disease Drug Bylvay Scores Back To Back Approvals In Europe, US.
- The net sales proceeds expected from the transaction are in addition to the $186.3 million in cash, cash equivalents, and short-term investments Albireo reported as of June 30, 2021.
- Price Action: ALBO shares are down 0.24% at $29.60 during the market session on the last check Tuesday.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.